MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$240,335K
Net Income
$7,781K
Net Profit Margin
3.24%
EPS
$0.05
Unit: Thousand (K) dollars
Revenue Breakdown
Product
License
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue
240,335
204,918
162,003*
161,709
Cost of revenue
41,194
33,510
30,168*
28,093
Stock-based compensation
8,070
4,875
2,139*
5,335
Other research and development
87,267
43,521
49,087*
35,543
Total research and development
95,337
48,396
51,225*
40,878
Stock-based compensation
19,805
15,075
11,461*
12,351
Other selling, general and administrative
62,325
73,142
42,138*
51,022
Total selling, general and administrative
82,130
88,217
53,598*
63,373
Total costs and expenses
218,661
170,123
134,990*
132,344
Operating income
21,674
34,795
27,013*
29,365
Interest expense
16,572
7,666
6,571*
6,721
Loss on extinguishment of debt
0
-9,153
-
-
Other income
5,132
2,387
1,706*
3,265
Total other expense
-11,440
-14,432
-4,865*
-3,456
Net income before taxes
10,234
20,363
22,147*
25,909
Income tax expense
2,453
586
203,591*
-364,986
Net income
7,781
19,777
-181,444
390,895
Basic EPS
0.05
0.14
-1.289
2.69
Diluted EPS
0.05
0.12
-1.129
2.43
Basic Average Shares
141,770,283
144,439,370
140,793,624
145,416,901
Diluted Average Shares
157,281,850
160,062,326
160,680,857
160,997,977
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Product
$235,794K
(69.83%↑ Y/Y)
License
$4,541K
Revenue
$240,335K
(70.27%↑ Y/Y)
Operating income
$21,674K
(-37.80%↓ Y/Y)
Total costs and
expenses
$218,661K
(105.69%↑ Y/Y)
Net income before
taxes
$10,234K
(-66.90%↓ Y/Y)
Total other expense
-$11,440K
(-191.61%↓ Y/Y)
Other income
$5,132K
(83.75%↑ Y/Y)
Total research and
development
$95,337K
(199.97%↑ Y/Y)
Total selling,
general and...
$82,130K
(47.76%↑ Y/Y)
Cost of revenue
$41,194K
(117.52%↑ Y/Y)
Net income
$7,781K
(-72.40%↓ Y/Y)
Income tax expense
$2,453K
(-10.25%↓ Y/Y)
Interest expense
$16,572K
(146.75%↑ Y/Y)
Other research and
development
$87,267K
(217.75%↑ Y/Y)
Stock-based compensation
$8,070K
(86.89%↑ Y/Y)
Other selling,
general and...
$62,325K
(43.14%↑ Y/Y)
Stock-based compensation
$19,805K
(64.44%↑ Y/Y)
Buy us a coffee
TG Therapeutics BRIUMVI Approval Call Slide Deck 12
TG THERAPEUTICS, INC. (TGTX)
TG Therapeutics BRIUMVI Approval Call Slide Deck 12
TG THERAPEUTICS, INC. (TGTX)